drugset / Trial / NCT00335192

To Determine if There Are Pharmacokinetic Interactions at Plasma or Intracellular Level Between Nucleosides and Tenofovir

NCT00335192

Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate if there are pharmacokinetic interactions between the NRTI 3TC and ABV, and the TDF nucleotide. For this purpose, the intracellular and plasma levels of 3TC and ABV will be compared in patients given these nucleosides with TDF and 30 days after the interruption of the TDF.

Timeline

Start
2005-01
Primary completion
2005-09
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified 300 mg
Subject Lamivudine Other / unclassified 300 mg
Subject Tenofovir disoproxil fumarate Small molecule
Background Lopinavir/ritonavir Unknown 400 mg